Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D933SC00001 / NILEA Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial CancerHotte, Dr SebastienOpen to recruitmentNCT03682068
(BMS) CA209-73MA Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction.Hotte, Dr SebastienOpen to recruitmentNCT04088500
(CCTG) BL.13A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder CancerLalani, Dr Aly-KhanOpen to recruitmentNCT03768570
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpen to recruitmentNCT03385655 (Master)
(CCTG) IND.234 / PC-BETS - Sub-Study IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT02905318
(CCTG) IND.234A/PC-BETS Sub-Study AA Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655 (A)
(CCTG) IND.234B/PC-BETS Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(B)
(CCTG) IND.234C/PC-BETS Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(C)
(CCTG) IND.234D/PC-BETS Sub-Study DA Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Mukherjee, Dr SomOpen to recruitmentNCT03385655(D)
(CCTG) IND.234E/PC-BETS Sub-Study EA Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)Mukherjee, Dr SomOpen to recruitmentNCT03385655(E)
(CCTG) IND.234F/PC-BETS Sub-Study FA Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (F)
(CCTG) IND.234G/PC-BETS Sub-Study GA Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (G)
(CCTG) PR.20A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)Quan, Dr KimmenOpen to recruitmentNCT03784755
(EXELIXIS) XL184-315 / CONTACT-02A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer.Hotte, Dr SebastienOpen to recruitmentNCT04446117
(JCC) The PBS StudyA randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa)Tsakiridis, Dr TheosOpen to recruitmentNCT03380806
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosOpen to recruitmentNCT02685397
(Merck) MK-3475-641 / KEYNOTE 641A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Lalani, Dr Aly-KhanOpen to recruitmentNCT03834493
(Merck) MK-6482-005An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted TherapiesLalani, Dr Aly-KhanOpen to recruitmentNCT04195750
(Merck) MK-7902-011 / LEAP-011 / E7080A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)Lalani, Dr Aly-KhanOpen to recruitmentNCT03898180
(UHN) WI222910 / ALPACAA Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based ChemotherapyMukherjee, Dr SomOpen to recruitmentNCT03391479
NRG-GU005 / HYPORTPhase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer.Dayes, Dr IanOpen to recruitmentNCT03367702
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomOpen to recruitmentNCT02462239
OCOG-2019-CYTOSHRINK / CA209-7DRCytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerLalani, Dr Aly-KhanOpen to recruitmentNCT04090710
(Basilea) DZB-CS-201 / FIDES-02An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients wtih urothelial cancer expressing activating molecular FGFR aberrations Hotte, Dr SebastienSuspended/On holdNCT04045613
(BMS) CA018005 / FRACTION-RCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Participants with Advanced Renal Cell Carcinoma
Hotte, Dr SebastienSuspended/On holdNCT02996110
(OHRI) RADIANT/OTT-19-07/OZM-105Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI 4736) prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)Lalani, Dr Aly-KhanSuspended/On holdNCT04543110
(Seattle Genetics) SGN22E-003 / EV-302An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus
chemotherapy alone in previously untreated locally advanced
or metastatic urothelial cancer
Hotte, Dr SebastienSuspended/On holdNCT04223856
Download PDF